BioCentury This Week
Kokonaiskesto:
21 h 29 min
Ep. 384 - Back to School Special: The global FIH trials race
BioCentury This Week
42:31
Ep. 383 - Moderna, Genentech obesity deal, Trump's FDA pick
BioCentury This Week
19:13
Ep. 382 - Summer’s venture wave; drugging beta-catenin; Capricor & FDA
BioCentury This Week
25:28
Ep. 381 - FIH urgency in the U.S. Plus: federated learning, biotech IPOs
BioCentury This Week
31:43
Ep. 380 - AZ-BMS rumors, Replimune, psychedelics
BioCentury This Week
32:25
Ep. 379 - Argenx M&A, AI giants and biopharma, catalyst scorecard
BioCentury This Week
34:09
Ep. 378 - U.K. cabinet shuffle, Taiwan biotech and Biogen data
BioCentury This Week
42:07
Ep. 377 - Trends in life sciences talent with CBRE's Ian Anderson
BioCentury This Week
29:16
Ep. 376 - M&A momentum: 3Q public markets preview
BioCentury This Week
33:01
Ep. 375 - Novartis' ADC gambit & regulation as catalyst for U.K. biotech
BioCentury This Week
33:44
Ep. 374 - Parkinson's deep dive & FDA trial reforms
BioCentury This Week
34:14
Ep. 373 - AbbVie M&A, FDA reversals, a CAR T first
BioCentury This Week
30:10
Ep. 372 - Biotech IPOs, Biosecure Act, cachexia pipeline
BioCentury This Week
25:13
Ep. 371 - Moving faster at the academia-industry interface
BioCentury This Week
32:43
Ep. 370 - Calmer waters for FDA; Servier, Lilly deals
BioCentury This Week
34:57
Ep. 369 - ASCO advances, China innovation & U.S. science under threat
BioCentury This Week
39:13
Ep. 368 - ASCO Preview, China Policy, ADC Linkers
BioCentury This Week
33:46
Ep. 367 - FDA, obesity targets and the rise of DACs
BioCentury This Week
30:40
Ep. 366 - Europe's need for speed: Bio€quity takeaways
BioCentury This Week
43:35
Ep. 365 - Thin ice for Makary, redosing AAVs
BioCentury This Week
30:45
Ep. 364 - UCB’s Candid buy, Grand Rounds and leukodystrophies
BioCentury This Week
32:15
Ep. 363 - New targets at AACR, biopharma deals, Kurma fund
BioCentury This Week
30:21
Ep. 362 - AACR: Data and de-risking
BioCentury This Week
25:06
Ep. 361 - Kelonia, Kailera, pyschedelics and T cell engagers
BioCentury This Week
44:02
Ep. 360 - FDA’s FIH plans. Plus: billion-dollar deals, funds
BioCentury This Week
33:38
Ep. 359 - 2Q markets preview, tariffs and biotech takeouts
BioCentury This Week
38:41
Ep. 358 - Europe's biotech challenge
BioCentury This Week
23:32
Ep. 357 - Deal-O-rama, Gilead and Tallon's U.K. vision
BioCentury This Week
28:38
Ep. 356 - Arrowhead’s arc. Plus: AI in biotech venture, Synnovation, MFN
BioCentury This Week
33:59
Ep. 355 - Capital market mood, Xenon data, Friedreich ataxia pipeline
BioCentury This Week
24:40
Ep. 354 - East-West Summit Takeaways
BioCentury This Week
26:21
Ep. 353 - Prasad Departure and Future of Fibrosis Therapies
BioCentury This Week
37:04
Ep. 352 - A Multipolar Biopharma World; Rare Disease Spotlight
BioCentury This Week
34:42
Ep. 351 - Gilead's Arcellx Buy. Plus: ctDNA as Surrogate Endpoint
BioCentury This Week
35:25
Ep. 350 - Oral SERD Spotlight. Plus: Setbacks at FDA
BioCentury This Week
26:16
Ep. 349 - Start-up Spotlight, Compounding Wegovy & Neuropysch
BioCentury This Week
33:55
Ep. 348 - Biotech's 2026 Catalysts. Plus: China's New Orphan Rules
BioCentury This Week
31:08
Ep. 347 - Speeding China's Innovation. Plus: Neuro Catalysts and Newcos
BioCentury This Week
29:48
Ep. 346 - 2026 Public Markets Preview
BioCentury This Week
30:54
Ep. 345 - TAC to the Future. Plus: GSK Deal, MFN
BioCentury This Week
30:33
